Regulatory FDA hands BeOne, Taiho approvals for blood cancers PharmaphorumBeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.HematologyRead full story pharminent May 14, 2026 (Last updated: May 21, 2026) Pharmaphorum BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho’s Inqovi has acute myeloid leukaemia added to its label. Hematology Read full story Post navigation Previous: Regulatory round-up: A month of key FDA approvals for cancer drugsNext: Regenxbio’s Duchenne gene therapy clears phase 3 hurdle Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
